Incubate Coalition: Life sciences investors react to first 10 drugs selected for government price controls
29 août 2023 08h44 HE
|
Incubate
Washington, DC, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Today, the Centers for Medicare & Medicaid Services announced the first 10 Medicare Part D drugs selected for government price setting under the...
Report from Incubate Policy Lab and Charles River Associates Finds Price Controls Would Decrease Investment in Critical Therapeutic Areas
18 nov. 2021 17h08 HE
|
Incubate
Washington, D.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Today, Incubate Policy Lab and Charles River Associates published a report detailing how investment into therapies for rare diseases and oncology...
Report from Incubate Policy Lab and Charles River Associates Finds Congressional Budget Office Underestimates Negative Impact of Drug Pricing Legislation
20 oct. 2021 10h09 HE
|
Incubate
Washington, D.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Today, Incubate Policy Lab and Charles River Associates published a report demonstrating that a leading proposal that would allow the federal...
Life Sciences Investors Sound the Alarm Over Drug Price Negotiations at Incubate Panel
16 sept. 2021 12h35 HE
|
Incubate
Washington, D.C., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Yesterday, a group of early-stage life science investors and biotech CEOs joined together with a prominent patient advocate to speak out against...
Biotech Investors Warn Against Innovation-Killing Policies at Expert Panel
18 déc. 2020 15h22 HE
|
Incubate
Washington, D.C., Dec. 18, 2020 (GLOBE NEWSWIRE) -- The federal government may soon kneecap the life sciences industry, prominent biotech investors warned Thursday during a panel discussion...
INCUBATE RAISES CONCERN ABUT PRESIDENT TRUMP'S EXECUTIVE ORDER ON DRUG PRICING
31 juil. 2020 17h10 HE
|
Incubate
Washington, DC, July 31, 2020 (GLOBE NEWSWIRE) -- Last week, President Trump signed four Executive Orders (EO) to lower prescription drug costs. One Executive Order was discussed that would import...